Showing 4121-4130 of 5911 results for "".
- Bausch + Lomb Completes Acquisition of Xiidrahttps://modernod.com/news/bausch-lomb-completes-acquisition-of-xiidra/2481861/Bausch + Lomb announced it has completed its acquisition of Xiidra (lifitegrast ophthalmic solution 5%), a non-steroid eye drop approved to treat the signs and symptoms of dry eye disease (DED) focusing on inflammation associated with dry eye. In June, Bausch + Lomb&
- Neurolens Introduces N3 VR-Based Measurement and Education Experiencehttps://modernod.com/news/neurolens-introduces-n3-vr-based-measurement-and-education-experience/2481854/Neurolens has introduced N3—a virtual reality experience designed to educate patients while measuring eye alignment. N3 provides an objective, accurate, and repeatable measurement of binocular alignment, which incorporates elements of heterophoria, fixation disparit
- Thea Pharma Announces the US Launch of Glaucoma Drug Iyuzehhttps://modernod.com/news/thea-pharma-announces-the-us-launch-of-glaucoma-drug-iyuzeh/2481850/Thea Pharma announced the launch and availability of Iyuzeh (latanoprost ophthalmic solution) 0.005% in the US market. Iyuzeh, which received FDA approval in December 2022, is the first and only preservative-free latanoprost for patients with primary open-angle glaucoma (
- PPG, Flō-Optics Announce Supplier Agreement for Digitally Applied Optical Coatingshttps://modernod.com/news/ppg-flo-optics-announce-supplier-agreement-for-digitally-applied-optical-coatings/2481849/PPG announced an exclusive supplier agreement with Flō-Optics, a developer of digital manufacturing technology for the ophthalmic industry, for the application of PPG HI-GARD scratch-resistant coatings using Flō’s proprietary digital printing technology. Financial terms of th
- Dopavision Completes Enrollment for MyopiaX-1 Trialhttps://modernod.com/news/dopavision-completes-enrollment-for-myopiax-1-trial/2481847/Dopavision, a clinical stage company developing solutions for myopia, announced the completion of enrollment in its MyopiaX-1 trial (NCT04967287). MyopiaX-1 is a randomized, active-controlled trial to evaluate the saf
- Bausch + Lomb Launches Lumify Eye Illuminations in the UShttps://modernod.com/news/bausch-lomb-launches-lumify-eye-illuminations-in-the-united-states/2481846/Bausch + Lomb announced the US launch of Lumify Eye Illuminations, a new line of hypoallergenic specialty eye care products developed to cleanse, nourish and brighten the sensitive eye area. “Many products contain chemicals or preservatives that can irritate the del
- OcuCell Announces Funding from the Georgia Eye Bankhttps://modernod.com/news/ocucell-announces-funding-from-the-georgia-eye-bank/2481845/OcuCell, a provider of ocular cell therapy, announce funding from the Georgia Eye Bank. Founded in 1961, Georgia Eye Bank has provided over 60,000 corneas for transplant and is dedicated to improving vision and lives through transplantation of ocular tissue and cells. Fin
- Apellis Receives Permanent J-Code for GA Drug Syfovrehttps://modernod.com/news/apellis-receives-permanent-j-code-for-ga-drug-syfovre/2481844/The U.S. Centers for Medicare & Medicaid Services (CMS) assigned a permanent and product-specific J-code (J2781) for Apellis Pharmaceuticals' Syfovre (pegcetacoplan injection), the first treatment for geographic atrophy (GA) secondary to age-related macular degeneration. The J-code f
- University of Toronto Researchers Build Online Glaucoma Simulatorhttps://modernod.com/news/university-of-toronto-researchers-build-online-glaucoma-simulator/2481843/Researchers at the University of Toronto have built an online simulator that is designed to give an improved visual representation of the deterioration caused by glaucoma. The simulator, built by Prof. Willy Wong and PhD candidat
- Pixium Vision Complete Reverse Stock Splithttps://modernod.com/news/pixium-vision-complete-reverse-stock-split/2481842/Pixium Vision announced the completion of a reverse stock split, as decided by its Board of Directors on July 27, 2023, on the basis of 1 new share for 50 existing shares. Shareholders who could not hold a multiple of 50 existing shares will be automatically compensated of their fractio